PR96010

TOKYO, May 16, 2022 /PRNewswire=KYODO JBN/ --

- Adjunctive use of Blood Glucose Meter Principally Not Required

Terumo Corporation (TSE: 4543) today announces that the indication for the

Dexcom G6 CGM System has changed in Japan as of May 10, 2022. With this new

indication, the Dexcom G6 CGM System will be the only real-time continuous

glucose monitoring system (RT-CGM) in Japan that can be used principally for

day-to-day management of blood glucose levels without the adjunctive use of a

blood glucose meter.

The Dexcom G6 CGM System is a RT-CGM developed and manufactured by Dexcom, Inc.

Terumo holds the exclusive distribution agreement for this product in Japan,

and it has been available for Japanese patients with diabetes since

2021(https://www.terumo.com/newsrelease/detail/20210727/625). Users attach a

small wearable sensor to the abdomen or other parts of the body so that glucose

values are continuously measured and automatically transmitted every five

minutes to a receiver or a smartphone with a dedicated app installed. Dexcom G6

CGM System users can constantly check their real-time glucose values and trends

with a visualized graph. The system can also notify users when blood glucose

values fall outside the target, as well as alert users when a severe

hypoglycemic event is predicted.

Previously in Japan the indication for Dexcom G6 CGM system was limited to

"assisting" blood glucose meters. As such, a blood glucose meter was required

for day-to-day diabetes management such as adjusting the amount of insulin

dozes. With the change in indication, a blood glucose meter is only required

"when necessary" and the Dexcom G6 CGM system can be utilized for users to make

everyday treatment decisions.

Yoshiya Kikawa, Division President of Terumo's Life Care Solution Division,

Medical Care Solutions Company comments, "With this new indication we hope more

patients will be able to manage their blood glucose value better and reduce the

risk of diabetic complications".

Terumo will continue to strive to improve the quality of life of patients and

advance medical systems based on its Group Mission of "Contributing to Society

Through Healthcare".

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been

committed to "Contributing to Society through Healthcare" for 100 years. Based

in Tokyo and operating globally, Terumo employs more than 25,000 associates

worldwide to provide innovative medical solutions in more than 160 countries

and regions. The company started as a Japanese thermometer manufacturer, and

has been supporting healthcare ever since. Now, its extensive business

portfolio ranges from vascular intervention and cardio-surgical solutions,

blood transfusion and cell therapy technology, to medical products essential

for daily clinical practice such as transfusion systems, diabetes care, and

peritoneal dialysis treatments. Terumo will further strive to be of value to

patients, medical professionals, and society at large.

SOURCE:  Terumo

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=421273

   Caption: Dexcom G6 CGM System